Table 4.
BOLTa, sonidegib 200 mg | ERIVANCEa, vismodegib 150 mg (n = 63) |
||
---|---|---|---|
Prematched (n = 66) |
Postmatched (n = 66) |
||
Matched baseline characteristics | |||
Prior BCC radiotherapy, nb (%) | 5 (7.6%) | (20.6%) | 13 (20.6%) |
Prior BCC surgery, nb (%) | 48 (72.7%) | (89.0%) | 56 (88.9%) |
| |||
Unmatched baseline characteristics | |||
Age in years | |||
Mean | 64.6 | 64.6 | 61.4 |
Median | 67.0 | 67.0 | 62.0 |
Standard deviation | 15.9 | 15.5 | 16.9 |
| |||
Age range in years, nb (%) | |||
18–40 | 6 (9.1%) | (8.6%) | 7 (11.1%) |
41–64 | 22 (33.3%) | (31.6%) | 26 (41.3%) |
≥65 | 38 (57.6%) | (59.8%) | 30 (47.6%) |
| |||
Race, nb (%) | |||
White | 59 (89.4%) | (90.8%) | (100.0%) |
Other | 7 (10.6%) | (9.2%) | (0.0%) |
| |||
ECOG status, nb,c (%) | |||
0 | 44 (66.7%) | (69.3%) | 48 (76.2%) |
1 | 16 (24.2%) | (21.5%) | 13 (20.6%) |
2 | 4 (6.1%) | (6.0%) | 2 (3.2%) |
| |||
Sex, nb (%) | |||
Male | 38 (57.6%) | (60.8%) | 35 (55.6%) |
Female | 28 (42.4%) | (39.2%) | 28 (44.4%) |
| |||
Prior systemic therapy for BCC, nb (%) | 4 (6.1%) | (5.4%) | 7 (11.1%)d |
BCC: basal cell carcinoma; ECOG: Eastern Cooperative Oncology Group. aBOLT data analysis was based on the 18-month update (i.e., 18 months of patient follow-up) [7]; ERIVANCE summary information was based on the 12-month update (i.e., 21 months of patient follow-up) [16]; bpostmatched BOLT results were weighted at the person level; therefore, the number of patients was not available; ctwo patients had missing ECOG status at baseline; dSystemic or topical.